Rafaele Tordjman
Founder & CEO @ Jeito Capital
Paris, France
Rafaele Tordjman is a Series B investor at Jeito Capital in Paris focused on Biotechnology and Therapeutics. Rafaele Tordjman is based out of Paris, Ile-de-France and is the Founder & CEO of Jeito Capital. Rafaele previously worked at Sofinnova Partners as a Special Advisor. Rafaele Tordjman attended the Université de Paris. Rafaele Tordjman has been awarded a Knight of the Legion of Honour.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Rafaele Tordjman invests in
Stages Rafaele Tordjman invests in
Countries Rafaele Tordjman invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 12 (57%)
- Therapeutics 7 (33%)
- Health Care 4 (19%)
- Medical 3 (14%)
- Pharmaceutical 3 (14%)
Stage
- Series B 8 (38%)
- Series A 7 (33%)
- Series C 3 (14%)
- Series D 1 (5%)
- Venture - Series Unknown 1 (5%)
Country
- France 4 (19%)
- Switzerland 3 (14%)
- United Kingdom 3 (14%)
- United States 2 (10%)
- Denmark 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively. | $207.5M / Series C / Jan 07, 2025 | ||
| Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies. | $147.2M / Series B / Dec 11, 2024 | ||
| Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases. | $181.4M / Series D / Nov 12, 2024 | ||
| NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need. | $81.4M / Series B / Nov 15, 2023 | ||
| Corteria Pharmaceuticals develops first-in-class drugs in heart failure subpopulations, focused on the development of transformative therapies for the treatment of worsening and acute decompensated heart failure. | $69.5M / Series A / Sep 07, 2023 | ||
| Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases. | $105M / Series C / Apr 13, 2023 | ||
| Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies. | $109.3M / Series B / Mar 07, 2023 | ||
| SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat allgenetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide. | $74.9M / Series B / Sep 14, 2022 | ||
| CDR-Life is a Zurich-based biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology and ophthalmology. Our facilities are located in the Bio-Technopark in Schlieren-Zurich, Switzerland | $76M / Series A / Apr 13, 2022 | ||
| NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.Importantly, the approach improves neuromuscular transmission in a way that ispotentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need. | $39.7M / Venture - Series Unknown / Feb 15, 2022 | ||
| See all 21 investments → | |||
Co-Investors
About Jeito Capital
Jeito Capital is a global investment company that invests in companies in the field of medical innovation. It focuses both on financing ground-breaking medical innovation and promoting positive societal impact. It empowers and supports entrepreneurs through its expert, integrated, multi-talented team.The company was founded in 2018 and is basedin Paris with a presence in Europe and the United States.
Jeito Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Rafaele Tordjman
Founder & CEO
|
|||
Julien Elric
Senior Principal
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Rafaele Tordjman invest in?
Rafaele Tordjman invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Series A stage. Most of the 21 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Rafaele Tordjman?
Public channels for Rafaele Tordjman include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Rafaele Tordjman last invest?
The most recent investment recorded for Rafaele Tordjman closed in Jan 2025. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
